In today’s briefing:
- Mesoblast (MSB AU): What Lies Ahead After FDA Approval
- Chemed Corporation: How Is The Management Tackling Roto-Rooter Challenges & Other Risks? -Major Drivers
Mesoblast (MSB AU): What Lies Ahead After FDA Approval
- Mesoblast Ltd (MSB AU) got FDA approval for Ryoncil for steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older.
- Following approval in pediatric patients, Mesoblast intends to commence a Phase 3 trial of Ryoncil in adults and adolescents, which has larger market size.
- FDA approval enhances conviction on the commercial prospect of the other late-stage product candidates of the company, including Revascor for advanced chronic heart failure and rexlemestrocel-L for inflammatory pain indications.
Chemed Corporation: How Is The Management Tackling Roto-Rooter Challenges & Other Risks? -Major Drivers
- Chemed Corporation’s third-quarter 2024 earnings present a mixed performance across its two primary business segments: VITAS Healthcare and Roto-Rooter.
- The company reports strong performance from VITAS, while Roto-Rooter is facing challenges.
- VITAS Healthcare displayed robust growth in the quarter, primarily driven by increased admissions and the successful acquisition of Covenant Health.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
